Peter Greenleaf Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Peter Greenleaf.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Peter Greenleaf. Peter Greenleaf is Senior VP, Sales & Marketing in MEDIMMUNE INC /DE ($MEDI) and SVP, Sales & Marketing in MEDIMMUNE INC /DE ($MEDI) and SVP, Sales and Marketing in MEDIMMUNE INC /DE ($MEDI) and Director in ANTARES PHARMA, INC. ($ATRS) and Director in BIODELIVERY SCIENCES INTERNATIONAL INC ($BDSI) and Director in Mast Therapeutics, Inc. ($MSTX) and CEO in Sucampo Pharmaceuticals, Inc. ($SCMP) and Chief Executive Officer in Sucampo Pharmaceuticals, Inc. ($SCMP) and Director in EYEGATE PHARMACEUTICALS INC ($EYEG) and Director in Mirna Therapeutics, Inc. ($MIRN) and in Cerecor Inc. ($CERC) and Chief Executive Officer in Cerecor Inc. ($CERC) and Director in Cerecor Inc. ($CERC) and Chief Executive Officer in Aurinia Pharmaceuticals Inc. ($AUPH).
Latest Insider Trading Transactions of Peter Greenleaf
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ATRS, AUPH, BDSI, CERC, EYEG, MEDI, SVRA, SCMP, SYBX
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 12 2021 | AUPH | Aurinia Pharmaceut ... | Greenleaf Peter | Chief Executive Off ... | Buy | P | 11.11 | 2,992 | 33,241 | 13,453 | 10.5 K to 13.5 K (+28.60 %) |
| May 12 2021 | AUPH | Aurinia Pharmaceut ... | Greenleaf Peter | Chief Executive Off ... | Buy | P | 10.15 | 2,133 | 21,650 | 10,461 | 8.3 K to 10.5 K (+25.61 %) |
| Aug 11 2020 | BDSI | BIODELIVERY SCIENC ... | Greenleaf Peter | Director | Option Exercise | M | 0.00 | 35,000 | 0 | 52,500 | |
| Aug 11 2020 | BDSI | BIODELIVERY SCIENC ... | Greenleaf Peter | Director | Buy | M | 0.00 | 35,000 | 0 | 59,788 | 24.8 K to 59.8 K (+141.20 %) |
| Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | Greenleaf Peter | Director | Option Exercise | A | 2.73 | 58,246 | 159,012 | 58,246 | |
| Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | Greenleaf Peter | Director | Grant | A | 2.73 | 30,220 | 82,501 | 54,193 | 24 K to 54.2 K (+126.06 %) |
| Oct 03 2019 | CERC | Cerecor Inc. | Greenleaf Peter | Director | Option Exercise | A | 2.93 | 25,000 | 73,250 | 25,000 | |
| Aug 15 2019 | BDSI | BIODELIVERY SCIENC ... | Greenleaf Peter | Director | Option Exercise | M | 0.00 | 21,144 | 0 | 87,500 | |
| Aug 15 2019 | BDSI | BIODELIVERY SCIENC ... | Greenleaf Peter | Director | Buy | M | 0.00 | 21,144 | 0 | 24,788 | 3.6 K to 24.8 K (+580.24 %) |
| Jun 14 2019 | ATRS | ANTARES PHARMA, IN ... | Greenleaf Peter | Director | Option Exercise | A | 2.92 | 46,729 | 136,449 | 46,729 | |
| Jun 14 2019 | ATRS | ANTARES PHARMA, IN ... | Greenleaf Peter | Director | Grant | A | 2.92 | 23,973 | 70,001 | 23,973 | 0 to 24 K |
| May 29 2019 | CERC | Cerecor Inc. | Greenleaf Peter | Director | Option Exercise | D | 4.24 | 500,000 | 2,120,000 | 0 | |
| May 29 2019 | CERC | Cerecor Inc. | Greenleaf Peter | Director | Option Exercise | D | 4.24 | 364,583 | 1,545,832 | 135,417 | |
| May 29 2019 | CERC | Cerecor Inc. | Greenleaf Peter | Director | Option Exercise | D | 6.22 | 325,000 | 2,021,500 | 0 | |
| May 29 2019 | CERC | Cerecor Inc. | Greenleaf Peter | Director | Sell | D | 0.00 | 300,000 | 0 | 112,500 | 412.5 K to 112.5 K (-72.73 %) |
| Apr 02 2019 | CERC | Cerecor Inc. | Greenleaf Peter | Chief Executive Off ... | Option Exercise | A | 6.22 | 325,000 | 2,021,500 | 325,000 | |
| Feb 05 2019 | EYEG | EYEGATE PHARMACEUT ... | Greenleaf Peter | Director | Option Exercise | A | 0.48 | 50,000 | 24,000 | 50,000 | |
| Dec 14 2018 | ATRS | ANTARES PHARMA, IN ... | Greenleaf Peter | Director | Option Exercise | A | 3.11 | 20,000 | 62,200 | 20,000 | |
| Aug 16 2018 | BDSI | BIODELIVERY SCIENC ... | Greenleaf Peter | Director | Option Exercise | M | 0.00 | 3,644 | 0 | 108,644 | |
| Aug 16 2018 | BDSI | BIODELIVERY SCIENC ... | Greenleaf Peter | Director | Buy | M | 0.00 | 3,644 | 0 | 3,644 | 0 to 3.6 K |
| Aug 08 2018 | EYEG | EYEGATE PHARMACEUT ... | Greenleaf Peter | Director | Option Exercise | A | 0.57 | 50,000 | 28,500 | 50,000 | |
| Aug 03 2018 | BDSI | BIODELIVERY SCIENC ... | Greenleaf Peter | Director | Option Exercise | A | 2.93 | 64,164 | 188,001 | 64,164 | |
| Aug 03 2018 | BDSI | BIODELIVERY SCIENC ... | Greenleaf Peter | Director | Option Exercise | A | 0.00 | 112,288 | 0 | 112,288 | |
| May 21 2018 | CERC | Cerecor Inc. | Greenleaf Peter | Chief Executive Off ... | Buy | P | 3.98 | 12,500 | 49,750 | 412,500 | 400 K to 412.5 K (+3.13 %) |
| Mar 29 2018 | CERC | Cerecor Inc. | Greenleaf Peter | Chief Executive Off ... | Option Exercise | A | 4.24 | 500,000 | 2,120,000 | 500,000 | |
| Mar 29 2018 | CERC | Cerecor Inc. | Greenleaf Peter | Chief Executive Off ... | Option Exercise | A | 4.24 | 500,000 | 2,120,000 | 500,000 | |
| Mar 29 2018 | CERC | Cerecor Inc. | Greenleaf Peter | Chief Executive Off ... | Grant | A | 0.00 | 400,000 | 0 | 400,000 | 0 to 400 K |
| Jan 04 2018 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | Chief Executive Off ... | Grant | A | 9.10 | 171 | 1,556 | 4,792 | 4.6 K to 4.8 K (+3.70 %) |
| Oct 05 2017 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | CEO | Grant | A | 9.10 | 659 | 5,997 | 4,621 | 4 K to 4.6 K (+16.63 %) |
| Jul 31 2017 | CERC | Cerecor Inc. | Greenleaf Peter | Option Exercise | A | 0.57 | 8,357 | 4,763 | 8,357 | ||
| Jul 07 2017 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | CEO | Grant | A | 8.93 | 673 | 6,010 | 3,962 | 3.3 K to 4 K (+20.46 %) |
| May 16 2017 | CERC | Cerecor Inc. | Greenleaf Peter | Director | Option Exercise | A | 0.80 | 16,714 | 13,371 | 16,714 | |
| May 10 2017 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | CEO | Grant | A | 9.35 | 641 | 5,993 | 3,289 | 2.6 K to 3.3 K (+24.21 %) |
| Mar 08 2017 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | Chief Executive Off ... | Option Exercise | A | 11.85 | 237,000 | 2,808,450 | 1,667,000 | |
| Mar 08 2017 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | Chief Executive Off ... | Grant | A | 0.00 | 125,000 | 0 | 125,000 | 0 to 125 K |
| Jan 23 2017 | MSTX | Mast Therapeutics, ... | Greenleaf Peter | Director | Option Exercise | A | 0.00 | 45,535 | 0 | 45,535 | |
| Jan 06 2017 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | Chief Executive Off ... | Grant | A | 10.46 | 135 | 1,412 | 2,648 | 2.5 K to 2.6 K (+5.37 %) |
| Nov 30 2016 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | CEO | Option Exercise | M | 6.75 | 82,459 | 556,598 | 1,430,000 | |
| Nov 30 2016 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | CEO | Option Exercise | M | 6.75 | 117,541 | 793,402 | 1,512,459 | |
| Nov 30 2016 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | CEO | Sell | S | 16.75 | 82,459 | 1,381,188 | 2,513 | 85 K to 2.5 K (-97.04 %) |
| Nov 30 2016 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | CEO | Buy | M | 6.75 | 82,459 | 556,598 | 84,972 | 2.5 K to 85 K (+3,281.30 %) |
| Nov 30 2016 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | CEO | Sell | S | 16.91 | 117,541 | 1,987,618 | 2,513 | 120.1 K to 2.5 K (-97.91 %) |
| Nov 30 2016 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | CEO | Buy | M | 6.75 | 117,541 | 793,402 | 120,054 | 2.5 K to 120.1 K (+4,677.32 %) |
| Oct 21 2016 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | Chief Executive Off ... | Grant | A | 9.38 | 640 | 6,003 | 2,513 | 1.9 K to 2.5 K (+34.17 %) |
| Sep 06 2016 | MIRN | Mirna Therapeutics ... | Greenleaf Peter | Director | Option Exercise | A | 4.74 | 10,000 | 47,400 | 10,000 | |
| Jul 18 2016 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | Chief Executive Off ... | Grant | A | 9.32 | 751 | 6,999 | 1,873 | 1.1 K to 1.9 K (+66.93 %) |
| Jun 17 2016 | MSTX | Mast Therapeutics, ... | Greenleaf Peter | Director | Option Exercise | A | 0.43 | 79,551 | 34,207 | 79,551 | |
| Jun 16 2016 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | Chief Executive Off ... | Grant | A | 9.29 | 646 | 6,001 | 1,122 | 476 to 1.1 K (+135.71 %) |
| Mar 04 2016 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | Chief Executive Off ... | Option Exercise | A | 13.80 | 420,000 | 5,796,000 | 1,630,000 | |
| Mar 04 2016 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | Chief Executive Off ... | Grant | A | 14.70 | 476 | 6,997 | 476 | 0 to 476 |
| Mar 14 2016 | MIRN | Mirna Therapeutics ... | Greenleaf Peter | Director | Option Exercise | A | 4.36 | 8,000 | 34,880 | 8,000 | |
| Mar 02 2016 | MIRN | Mirna Therapeutics ... | Greenleaf Peter | Director | Option Exercise | A | 4.55 | 12,000 | 54,600 | 12,000 | |
| Nov 09 2015 | MSTX | Mast Therapeutics, ... | Greenleaf Peter | Director | Option Exercise | A | 0.45 | 37,794 | 17,007 | 37,794 | |
| Nov 09 2015 | MSTX | Mast Therapeutics, ... | Greenleaf Peter | Director | Option Exercise | A | 0.45 | 64,791 | 29,156 | 64,791 | |
| Mar 13 2015 | SCMP | Sucampo Pharmaceut ... | Greenleaf Peter | Chief Executive Off ... | Option Exercise | A | 14.82 | 210,000 | 3,112,200 | 1,210,000 | |
| Jun 19 2007 | MEDI | MEDIMMUNE INC /DE | Greenleaf Peter | SVP, Sales and Mark ... | Option Exercise | D | 31.25 | 60,000 | 1,875,000 | 0 | |
| Jun 19 2007 | MEDI | MEDIMMUNE INC /DE | Greenleaf Peter | SVP, Sales and Mark ... | Option Exercise | D | 30.38 | 70,000 | 2,126,600 | 0 | |
| Feb 20 2007 | MEDI | MEDIMMUNE INC /DE | Greenleaf Peter | Senior VP, Sales & ... | Option Exercise | A | 31.25 | 60,000 | 1,875,000 | 60,000 | |
| May 23 2006 | MEDI | MEDIMMUNE INC /DE | Greenleaf Peter | SVP, Sales & Market ... | Option Exercise | M | 30.38 | 70,000 | 2,126,600 | 70,000 |
Page: 1